BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 18713227)

  • 1. Hansen's disease in Portugal: multibacillary patients treated between 1988 and 2003.
    Medeiros S; Catorze MG; Vieira MR
    J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):29-35. PubMed ID: 18713227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
    Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
    Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
    Mane I; Cartel JL; Grosset JH
    Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of multidrug therapy on leprosy in Baroda district (Gujarat).
    Chopra NK; Agarwal JS; Pandya PG
    Indian J Lepr; 1989 Apr; 61(2):179-89. PubMed ID: 2746026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
    Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients.
    Kaur I; Dogra S; Kumar B; Radotra BD
    Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):174-81. PubMed ID: 12483965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
    Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
    Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
    Katoch K; Natarajan M; Bagga A; Katoch VM
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
    Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
    Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of MDT in multibacillary leprosy.
    Jesudasan K; Vijayakumaran P; Manimozhi N; Rao PS; Samuel P
    Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):128-32. PubMed ID: 8690970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed duration MDT in paucibacillary leprosy.
    Mathai R; George S; Jacob M
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):237-41. PubMed ID: 2071980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problems of leprosy relapse in China.
    Li HY
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):1-7. PubMed ID: 8326169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of relapse in multibacillary patients after cessation of long-course dapsone monotherapy supplemented by a final supervised single dose of 1500 mg of rifampin.
    Cartel JL; Naudin JC
    Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):215-9. PubMed ID: 8046260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.